Clare L. Scott

Genomic alterations enable BRCA1 methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancer

This study identifies genomic mechanisms enabling BRCA1 methylation loss and promoter bypass in ovarian cancer, leading to PARP inhibitor resistance.

Comprehensive drug efficacy data for mucinous ovarian carcinoma using a novel and extensive biobank of patient-derived organoid models

This paper develops a large biobank of patient-derived MOC organoids and screens them for drug efficacy, finding resistance to standard therapies and effectiveness of less commonly used drugs.

Demethylating agents drive PARP inhibitor resistance in ovarian carcinomas with BRCA1 gene silencing

This study shows that DNMT1 inhibitors reduce BRCA1 promoter methylation in HGSOC, leading to BRCA1 re-expression and PARP inhibitor resistance.

Local nucleolar surveillance mechanisms maintain rDNA stability

This study identifies localized nucleolar surveillance mechanisms that respond to rDNA damage by activating the nucleolar DNA damage response (nDDR) through R-loop formation and RAD54L protection.

Generation of a PARPi-sensitive homozygous BRCA1-methylated OVCAR8 cell line using targeted CRISPR gene editing

The paper generates a homozygous BRCA1-methylated OVCAR8 cell line using CRISPR editing to study meBRCA1 stability and PARPi resistance.

A Risk-reward Examination of Sample Multiplexing Reagents for Single Cell RNA-Seq

This study evaluates sample multiplexing reagents and protocols for scRNA-Seq, finding that workflow improvements and reagent choice impact data quality and cost-effectiveness.